Global Prostate Cancer Therapeutics Market to 2020
Global Prostate Cancer Therapeutics Market Overview
The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.
Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.
Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.
The report covers the following:
1. Global Prostate Cancer – Hormonal Therapy Drugs Market
Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
1. Zytiga
2. Gonax
Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
1. Lupron
2. Zoladex
3. Decapeptyl
4. Eligard
5. Vantas
6. Leuplin
Anti–Androgens
1. Casodex
2. Xtandi or MDV3100
3. Xtandi US or MDV3100
2. Global Prostate Cancer Chemotherapy Drugs Market
1. Taxotere
2. Jevtana
3. Global Prostate Cancer Immunotherapy Drugs Market–
1. Provenge
4. Global Prostate Cancer Targeted Therapy Drugs Market–
1. Xofigo or Alpharadin
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
The prostate cancer drugs market is expected to nearly double by 2020, due to the introduction of new, more expensive drugs. Prostate Cancer is the most frequently diagnosed cancer in men. In terms of loss of life from any disease, prostate cancer ranks eleventh; and it ranks sixth in terms of cancer–related mortality in men. The prostate cancer market has a huge demand for new and novel drugs that address unmet needs such as improved survival time, less toxicity, increased progression free survival, increased effectiveness, and lower cost. The global market for the prostate cancer therapeutics market is increasing, driven primarily by the growth in the hormone–refractory prostate cancer therapeutics market. Although, the prostate cancer market faces some hindrances such as the high cost of prostate cancer drugs, the market for prostate cancer drugs is likely to rise in the future.
Global Prostate Cancer Drugs Analysis: Zytiga was the leading prostate cancer drugs in 2014 being followed by Xtandi drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position respectively in 2014, while Lupron stands at the fifth position in the same year. Bayer's cancer drug Xofigo is also increasing its market share. Decapeptyl, Taxotere, Jevtana and Provenge are the other popular prostate cancer drugs in the global market.
Renub Research report titled “Global Prostate Cancer Therapeutics Market to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Prostate Cancer Therapeutics Market. This 80 page report with 35 Figures and 2 Tables analyses the Prostate Cancer Therapy Drugs Market, driving factors and challenges for prostate cancer market landscape.
The report covers the following:
1. Global Prostate Cancer – Hormonal Therapy Drugs Market
Luteinizing Hormone–Releasing Hormone (LHRH) Antagonists
1. Zytiga
2. Gonax
Luteinizing Hormone–Releasing Hormone (LHRH) Analogs
1. Lupron
2. Zoladex
3. Decapeptyl
4. Eligard
5. Vantas
6. Leuplin
Anti–Androgens
1. Casodex
2. Xtandi or MDV3100
3. Xtandi US or MDV3100
2. Global Prostate Cancer Chemotherapy Drugs Market
1. Taxotere
2. Jevtana
3. Global Prostate Cancer Immunotherapy Drugs Market–
1. Provenge
4. Global Prostate Cancer Targeted Therapy Drugs Market–
1. Xofigo or Alpharadin
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
1. EXECUTIVE SUMMARY
2. PROSTATE CANCER – OVERVIEW
2.1 Prostate Cancer Introduction
2.2 Risk Factors
2.2.1 Age
2.2.2 Race
2.2.3 Family History/Genetics
2.2.4 Diet/Lifestyle Factors
2.2.5 Obesity
2.2.6 Infection/Inflammation of the Prostate Gland
2.3 Disease Symptoms
2.4 Diagnosis
2.4.1 Digital Rectal Exam (DRE)
2.4.2 Prostate Specific Antigen (PSA) Blood Test
2.4.3 Prostate Ultrasound and Biopsy
2.4.4 Bone Scan
2.4.5 CT Scan & MRI
2.4.6 PET & SPECT Scan
2.4.7 Lymph Node Biopsy
2.4.8 ProstaScint Scan
2.5 Stages of Prostate Cancer
2.5.1 Stage I
2.5.2 Stage II
2.5.3 Stage III
2.5.4 Stage IV
3. GLOBAL PROSTATE CANCER DRUGS MARKET
4. GLOBAL PROSTATE CANCER INCIDENCE
5. GLOBAL PROSTATE CANCER DRUGS MARKET SHARE
6. GLOBAL PROSTATE CANCER – HORMONAL THERAPY DRUGS SALES & FORECAST TO 2020
6.1 Luteinizing Hormone – Releasing Hormone (LHRH) Antagonists
6.1.1 Zytiga
6.1.2 Gonax / Firmagon
6.2 Luteinizing Hormone – Releasing Hormone (LHRH) Analogs
6.2.1 Lupron
6.2.2 Zoladex
6.2.3 Decapeptyl
6.2.4 Eligard
6.2.5 Vantas
6.2.6 Leuplin
6.3 Anti – Androgens
6.3.1 Casodex
6.3.2 Xtandi or MDV3100
6.3.3 Xtandi US or MDV3100
7. GLOBAL PROSTATE CANCER – CHEMOTHERAPY DRUGS MARKET
7.1 Taxotere
7.2 Jevtana
8. GLOBAL PROSTATE CANCER – IMMUNOTHERAPY DRUGS MARKET
8.1 Provenge
9. GLOBAL PROSTATE CANCER – TARGETED THERAPY DRUGS MARKET
9.1 Xofigo or Alpharadin
10. GLOBAL PROSTATE CANCER MARKET – DRIVING FACTORS
10.1 Introduction of Innovative Drugs
10.2 Advancement in Oncology Therapeutic Area
10.3 Development in Genomics & Proteomics
11. GLOBAL PROSTATE CANCER MARKET – CHALLENGES
11.1 Costly Prostate Cancer Drugs
11.2 Adverse Events of Treatment
11.3 Low Success Rate for Oncology Drugs
2. PROSTATE CANCER – OVERVIEW
2.1 Prostate Cancer Introduction
2.2 Risk Factors
2.2.1 Age
2.2.2 Race
2.2.3 Family History/Genetics
2.2.4 Diet/Lifestyle Factors
2.2.5 Obesity
2.2.6 Infection/Inflammation of the Prostate Gland
2.3 Disease Symptoms
2.4 Diagnosis
2.4.1 Digital Rectal Exam (DRE)
2.4.2 Prostate Specific Antigen (PSA) Blood Test
2.4.3 Prostate Ultrasound and Biopsy
2.4.4 Bone Scan
2.4.5 CT Scan & MRI
2.4.6 PET & SPECT Scan
2.4.7 Lymph Node Biopsy
2.4.8 ProstaScint Scan
2.5 Stages of Prostate Cancer
2.5.1 Stage I
2.5.2 Stage II
2.5.3 Stage III
2.5.4 Stage IV
3. GLOBAL PROSTATE CANCER DRUGS MARKET
4. GLOBAL PROSTATE CANCER INCIDENCE
5. GLOBAL PROSTATE CANCER DRUGS MARKET SHARE
6. GLOBAL PROSTATE CANCER – HORMONAL THERAPY DRUGS SALES & FORECAST TO 2020
6.1 Luteinizing Hormone – Releasing Hormone (LHRH) Antagonists
6.1.1 Zytiga
6.1.2 Gonax / Firmagon
6.2 Luteinizing Hormone – Releasing Hormone (LHRH) Analogs
6.2.1 Lupron
6.2.2 Zoladex
6.2.3 Decapeptyl
6.2.4 Eligard
6.2.5 Vantas
6.2.6 Leuplin
6.3 Anti – Androgens
6.3.1 Casodex
6.3.2 Xtandi or MDV3100
6.3.3 Xtandi US or MDV3100
7. GLOBAL PROSTATE CANCER – CHEMOTHERAPY DRUGS MARKET
7.1 Taxotere
7.2 Jevtana
8. GLOBAL PROSTATE CANCER – IMMUNOTHERAPY DRUGS MARKET
8.1 Provenge
9. GLOBAL PROSTATE CANCER – TARGETED THERAPY DRUGS MARKET
9.1 Xofigo or Alpharadin
10. GLOBAL PROSTATE CANCER MARKET – DRIVING FACTORS
10.1 Introduction of Innovative Drugs
10.2 Advancement in Oncology Therapeutic Area
10.3 Development in Genomics & Proteomics
11. GLOBAL PROSTATE CANCER MARKET – CHALLENGES
11.1 Costly Prostate Cancer Drugs
11.2 Adverse Events of Treatment
11.3 Low Success Rate for Oncology Drugs
LIST OF FIGURES:
Figure 3–1: Global – Prostate Cancer Drugs Market (Million US$), 2010 – 2014
Figure 3–2: Global – Forecast for Prostate Cancer Drugs Market (Million US$), 2015 – 2020
Figure 4–1: Global – Prostate Cancer Incidence (Number), 2007 – 2014
Figure 4–2: Global – Forecast for Prostate Cancer Incidence (Number), 2015 – 2020
Figure 6–1: Global – Zytiga Drugs Sales (Million US$), 2011 – 2014
Figure 6–2: Global – Forecast for Zytiga Drugs Sales (Million US$), 2015 – 2020
Figure 6–3: Global – Gonax/ Firmagon Drugs Sales (Million US$), 2012 – 2014
Figure 6–4: Global – Forecast for Gonax Drugs Sales (Million US$), 2015 – 2020
Figure 6–5: Global – Lupron Drugs Sales (Million US$), 2009 – 2014
Figure 6–6: Global – Forecast for Lupron Drugs Sales (Million US$), 2015 – 2020
Figure 6–7: Global – Zoladex Drugs Sales (Million US$), 2009 – 2014
Figure 6–8: Global – Forecast for Zoladex Drugs Sales (Million US$), 2015 – 2020
Figure 6–9: Global – Decapeptyl Drugs Sales (Million US$), 2009 – 2014
Figure 6–10: Global – Forecast for Decapeptyl Drugs Sales (Million US$), 2015 – 2020
Figure 6–11: Global – Eligard Drug Sales (Million US$), 2009 – 2014
Figure 6–12: Global – Forecast for Eligard Drug Sales (Million US$), 2015 – 2020
Figure 6–13: Global – Vantas Drugs Sales (Million US$), 2009 – 2014
Figure 6–14: Global – Forecast for Vantas Drugs Sales (Million US$), 2015 – 2020
Figure 6–15: Global – Leuplin Drugs Sales (Million US$), 2009 – 2014
Figure 6–16: Global – Forecast for Leuplin Drugs Sales (Million US$), 2015 – 2020
Figure 6–17: Global – Casodex Drug Sales (Million US$), 2009 – 2014
Figure 6–18: Global – Forecast for Casodex Drug Sales (Million US$), 2015 – 2020
Figure 6–19: Global – Xtandi or MDV3100 Drug Sales (Million US$), 2012 – 2014
Figure 6–20: Global – Forecast for Xtandi or MDV3100 Drug Sales (Million US$), 2015 – 2020
Figure 6–21: Global – Xtandi US or MDV3100 Drug Sales (Million US$), 2012 – 2014
Figure 6–22: Global – Forecast for Xtandi US or MDV3100 Drug Sales (Million US$), 2015 – 2020
Figure 7–1: Global – Taxotere Drug Sales (Million US$), 2011 – 2014
Figure 7–2: Global – Forecast for Taxotere Drug Sales (Million US$), 2015 – 2020
Figure 7–3: Global – Jevtana Drug Sales (Million US$), 2010 – 2014
Figure 7–4: Global – Forecast for Jevtana Drug Sales (Million US$), 2015 – 2020
Figure 8–1: Global – Provenge Drugs Sales (Million US$), 2011 – 2014
Figure 8–2: Global – Forecast for Provenge Drugs Sales (Million US$), 2015 – 2020
Figure 9–1: Global – Xofigo or Alpharadin Drug Sales (Million US$), 2013 – 2014
Figure 9–2: Global – Forecast for Xofigo or Alpharadin Drug Sales (Million US$), 2015 – 2020
Figure 11–1: Therapeutic Categories – Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 – 2010
Figure 3–1: Global – Prostate Cancer Drugs Market (Million US$), 2010 – 2014
Figure 3–2: Global – Forecast for Prostate Cancer Drugs Market (Million US$), 2015 – 2020
Figure 4–1: Global – Prostate Cancer Incidence (Number), 2007 – 2014
Figure 4–2: Global – Forecast for Prostate Cancer Incidence (Number), 2015 – 2020
Figure 6–1: Global – Zytiga Drugs Sales (Million US$), 2011 – 2014
Figure 6–2: Global – Forecast for Zytiga Drugs Sales (Million US$), 2015 – 2020
Figure 6–3: Global – Gonax/ Firmagon Drugs Sales (Million US$), 2012 – 2014
Figure 6–4: Global – Forecast for Gonax Drugs Sales (Million US$), 2015 – 2020
Figure 6–5: Global – Lupron Drugs Sales (Million US$), 2009 – 2014
Figure 6–6: Global – Forecast for Lupron Drugs Sales (Million US$), 2015 – 2020
Figure 6–7: Global – Zoladex Drugs Sales (Million US$), 2009 – 2014
Figure 6–8: Global – Forecast for Zoladex Drugs Sales (Million US$), 2015 – 2020
Figure 6–9: Global – Decapeptyl Drugs Sales (Million US$), 2009 – 2014
Figure 6–10: Global – Forecast for Decapeptyl Drugs Sales (Million US$), 2015 – 2020
Figure 6–11: Global – Eligard Drug Sales (Million US$), 2009 – 2014
Figure 6–12: Global – Forecast for Eligard Drug Sales (Million US$), 2015 – 2020
Figure 6–13: Global – Vantas Drugs Sales (Million US$), 2009 – 2014
Figure 6–14: Global – Forecast for Vantas Drugs Sales (Million US$), 2015 – 2020
Figure 6–15: Global – Leuplin Drugs Sales (Million US$), 2009 – 2014
Figure 6–16: Global – Forecast for Leuplin Drugs Sales (Million US$), 2015 – 2020
Figure 6–17: Global – Casodex Drug Sales (Million US$), 2009 – 2014
Figure 6–18: Global – Forecast for Casodex Drug Sales (Million US$), 2015 – 2020
Figure 6–19: Global – Xtandi or MDV3100 Drug Sales (Million US$), 2012 – 2014
Figure 6–20: Global – Forecast for Xtandi or MDV3100 Drug Sales (Million US$), 2015 – 2020
Figure 6–21: Global – Xtandi US or MDV3100 Drug Sales (Million US$), 2012 – 2014
Figure 6–22: Global – Forecast for Xtandi US or MDV3100 Drug Sales (Million US$), 2015 – 2020
Figure 7–1: Global – Taxotere Drug Sales (Million US$), 2011 – 2014
Figure 7–2: Global – Forecast for Taxotere Drug Sales (Million US$), 2015 – 2020
Figure 7–3: Global – Jevtana Drug Sales (Million US$), 2010 – 2014
Figure 7–4: Global – Forecast for Jevtana Drug Sales (Million US$), 2015 – 2020
Figure 8–1: Global – Provenge Drugs Sales (Million US$), 2011 – 2014
Figure 8–2: Global – Forecast for Provenge Drugs Sales (Million US$), 2015 – 2020
Figure 9–1: Global – Xofigo or Alpharadin Drug Sales (Million US$), 2013 – 2014
Figure 9–2: Global – Forecast for Xofigo or Alpharadin Drug Sales (Million US$), 2015 – 2020
Figure 11–1: Therapeutic Categories – Overall Success Rate from Phase 1 through Likelihood of Approval (Percent), 2004 – 2010
LIST OF TABLES:
Table 5–1: Global – Prostate Cancer Drugs Market Share (Percent), 2011 – 2014
Table 5–2: Global – Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 – 2020
Table 5–1: Global – Prostate Cancer Drugs Market Share (Percent), 2011 – 2014
Table 5–2: Global – Forecast for Prostate Cancer Drugs Market Share (Percent), 2015 – 2020
